Survivin nuclear labeling index: A superior biomarker in superficial urothelial carcinoma of human urinary bladder

Modern Pathology

Volumn 19, Issue 11, 2006, Pages 1487-1497

  Yin, Wu ^a   Chen, Ni ^a   Zhang, Yutao ^a   Zeng, Hao ^a   Chen, Xueqin ^a   He, Yongtao ^a   Wang, Xiaojie ^a   Zhou, Qiao ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Prognosis; Survivin BIRC5; Urinary bladder; Urothelial carcinoma

Indexed keywords

APOPTOTIC PROTEASE ACTIVATING FACTOR 1; CASPASE 10; CASPASE 14; CASPASE 3; CASPASE 6; CASPASE 7; CASPASE 8; CASPASE 9; CELLULAR INHIBITOR OF APOPTOSIS PROTEIN 1; CELLULAR INHIBITOR OF APOPTOSIS PROTEIN 2; KI 67 ANTIGEN; LIVIN; PROTEIN; PROTEIN BCL 2; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; SURVIVIN; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

AGED; ARTICLE; BLADDER CARCINOMA; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; RISK FACTOR; STAINING; UNIVARIATE ANALYSIS; UROTHELIUM;

AGED; APOPTOSIS; BLOTTING, WESTERN; CELL NUCLEUS; CELL PROLIFERATION; COHORT STUDIES; CYTOPLASM; EVALUATION STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOPLASM STAGING; ODDS RATIO; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 33750300761     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.3800675     Document Type: Article

References (51)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics. CA Cancer J Clin 2005;55:10-30.
2. Stein JP, Grossfeld GD, Ginsberg DA, et al. Prognostic markers in bladder cancer: a contemporary review of the literature. J Urol 1998;160:645-659.
3. Eble JN, Sauter G, Epstein JI, et al. (eds). World Health Organization classification of tumours. Pathology and genetics of the urinary system and male genital organs. IARC Press: Lyon, France, 2004, pp 89-123.
4. Bush C, Price P, Norton J, et al. Proliferation in human bladder carcinoma measured by Ki-67 antibody labeling: its potential clinical importance. Br J Cancer 1991;64:357-360.
5. Glick SH, Howell LP, White RW. Relationship of p53 and bcl-2 to prognosis in muscle-invasive transitional cell carcinoma of the bladder. J Urol 1996;155:1754-1757.
6. King ED, Matteson J, Jacobs SC, et al. Incidence of apoptosis, cell proliferation and bcl-2 expression in transitional cell carcinoma of the bladder: association with tumor progression. J Urol 1996;155:316-320.
7. Shiina H, Igawa M, Urakami S, et al. Immunohistochemical analysis of bcl-2 expression in transitional cell carcinoma of the bladder. J Clin Pathol 1996;49:395-399.
8. Gazzaniga P, Gradilone A, Vercillo R. Bcl-2/bax mRNA expression ratio as prognostic factor in low-grade urinary bladder cancer. Int J Cancer 1996;69:100-104.
9. Lipponen PK, Aaltomaa S, Eskelinen M. Expression of the apoptosis suppressing bcl-2 protein in transitional cell bladder tumours. Histopathology 1996;28:135-140.
10. Liukkonen T, Rajala P, Raitanen M, et al. Prognostic value of MIB-1 score, p53, EGFr, mitotic index and papillary status in primary superficial (Stage pTa/T1) bladder cancer: a prospective comparative study. Eur Urol 1999;36:393-400.
11. Tsuji M, Kojima K, Murakami Y, et al. Prognostic value of Ki-67 antigen and p53 protein in urinary bladder cancer: immunohistochemical analysis of radical cystectomy specimens. Br J Urol 1997;79:367-372.
12. Nakopoulou L, Vourlakou C, Zervas A, et al. The prevalence of bcl-2, p53, and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathological correlates. Hum Pathol 1998;29:146-154.
13. Tzai TS, Chow NH, Lin JS, et al. The expression of p53 and bcl-2 in superficial bladder transitional cell carcinoma and its role in the outcome of postoperative intravesical chemotherapy. Anticancer Res 1998;18:4717-4721.
14. Zlotta AR, Noel JC, Fayt I, et al. Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy. J Urol 1999;161:792-798.
15. Pfister C, Lacombe L, Vezina MC, et al. Prognostic value of the proliferative index determined by Ki-67 immunostaining in superficial bladder tumors. Hum Pathol 1999;30:1350-1355.
16. Wu TT, Chen JH, Lee YH, et al. The role of bcl-2, p53, and ki-67 index in predicting tumor recurrence for low grade superficial transitional cell bladder carcinoma. J Urol 2000;163:758-760.
17. Gontero P, Casetta G, Zitella A, et al. Evaluation of P53 protein overexpression, Ki67 proliferative activity and mitotic index as markers of tumour recurrence in superficial transitional cell carcinoma of the bladder. Eur Urol 2000;38:287-296.
18. Korkolopoulou P, Lazaris ACh, Konstantinidou AE, et al. Differential expression of bcl-2 family proteins in bladder carcinomas. Relationship with apoptotic rate and survival. Eur Urol 2002;41:274-283.
19. Rodel C, Grabenbauer GG, Rodel F, et al. Apoptosis, p53, bcl-2, and Ki-67 in invasive bladder carcinoma: possible predictors for response to radiochemotherapy and successful bladder preservation. Int J Radiat Oncol Biol Phys 2000;46:1213-1221.
20. Ong F, Moonen LM, Gallee MP, et al. Prognostic factors in transitional cell cancer of the bladder: an emerging role for Bcl-2 and p53. Radiother Oncol 2001;61:169-175.
21. Rodriguez-Alonso A, Pita-Fernandez S, Gonzalez-Carrero J, et al. p53 and ki67 expression as prognostic factors for cancer-related survival in stage T1 transitional cell bladder carcinoma. Eur Urol 2002;41:182-188.
22. Bilim V, Kasahara T, Hara N, et al. Role of XIAP in the malignant phenotype of transitional cell cancer (TCC) and therapeutic activity of XIAP antisense oligonucleotides against multidrug-resistant TCC in vitro. Int J Cancer 2003;103:29-37.
23. Schultz IJ, Kiemeney LA, Witjes JA, et al. Survivin mRNA expression is elevated in malignant urothelial cell carcinomas and predicts time to recurrence. Anticancer Res 2003;23:3327-3331.
24. Gazzaniga P, Gradilone A, Giuliani L, et al. Expression and prognostic significance of LIVIN, SURVIVIN and other apoptosis-related genes in the progression of superficial bladder cancer. Ann Oncol 2003;14:85-90.
25. Lopez-Beltran A, Luque RJ, Alvarez-Kindelan J, et al. Prognostic factors in stage T1 grade 3 bladder cancer survival: the role of G1-S modulators (p53, p21Waf1, p27kip1, Cyclin D1, and Cyclin D3) and proliferation index (ki67-MIB1). Eur Urol 2004;45:606-612.
26. Ku JH, Kwak C, Lee HS, et al. Expression of survivin, a novel inhibitor of apoptosis, in superficial transitional cell carcinoma of the bladder. J Urol 2004;171:631-635.
27. Weikert S, Christoph F, Schrader M, et al. Quantitative analysis of survivin mRNA expression in urine and tumor tissue of bladder cancer patients and its potential relevance for disease detection and prognosis. Int J Cancer 2005;116:100-104.
28. Salvesen GS, Abrams JM. Caspase activation-stepping on the gas or releasing the brakes? Lessons from humans and flies. Oncogene 2004;23:2774-2784.
29. Shi Y. Caspase activation, inhibition, and reactivation: a mechanistic view. Protein Sci 2004;13:1979-1987.
30. Riedl SJ, Shi Y. Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol 2004;5:897-907.
31. Schimmer AD. Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Res 2004;64:7183-7190.
32. Salvesen GS, Duckett CS. IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol 2002;3:401-410.
33. Wang X. The expanding role of mitochondria in apoptosis. Genes Dev 2001;15:2922-2933.
34. Fuessel S, Kueppers B, Ning S, et al. Systematic in vitro evaluation of survivin directed antisense oligodeoxynucleotides in bladder cancer cells. J Urol 2004;171:2471-2476.
35. Miller RT, Kubier P. Blocking of endogenous avidin-binding activity in immunohistochemistry: The use of skim milk as an economical and effective substitute for commercial biotin solutions. Appl Immunohistochem Mol Morphol 1999;7:63-65.
36. Nielsen TO, Hsu FD, O'Connell JX, et al. Tissue microarray validation of epidermal growth factor receptor and SALL2 in synovial sarcoma with comparison to tumors of similar histology. Am J Pathol 2003;163:1449-1456.
37. Smith SD, Wheeler MA, Plescia J, et al. Urine detection of survivin and diagnosis of bladder cancer. JAMA 2001;285:324-328.
38. Shariat SF, Casella R, Khoddami SM, et al. Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. J Urol 2004;171:626-630.
39. Persad R, Liu C, Wu TT, et al. Overexpression of caspase-3 in hepatocellular carcinomas. Mod Pathol 2004;17:861-867.
40. Yang L, Cao Z, Yan H, et al. Coexistence of high levels of apoptotic signaling and inhibitor of apoptosis proteins in human tumor cells: implication for cancer specific therapy. Cancer Res 2003;63:6815-6824.
41. Li F, Ambrosini G, Chu EY, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998;396:580-584.
42. Altieri DC. Molecular circuits of apoptosis regulation and cell division control: the survivin paradigm. J Cell Biochem 2004;92:656-663.
43. Preusser M, Wolfsberger S, Czech T, et al. Survivin expression in intracranial ependymomas and its correlation with tumor cell proliferation and patient outcome. Am J Clin Pathol 2005;124:543-549.
44. Lehner R, Lucia MS, Jarboe EA, et al. Immunohistochemical localization of the IAP protein survivin in bladder mucosa and transitional cell carcinoma. Appl Immunohistochem Mol Morphol 2002;10:134-138.
45. Grabowski P, Kuhnel T, Muhr-Wilkenshoff F, et al. Prognostic value of nuclear survivin expression in oesophageal squamous cell carcinoma. Br J Cancer 2003;88:115-119.
46. Lu B, Gonzalez A, Massion PP, et al. Nuclear survivin as a biomarker for non-small-cell lung cancer. Br J Cancer 2004;91:537-540.
47. Martinez A, Bellosillo B, Bosch F, et al. Nuclear survivin expression in mantle cell lymphoma is associated with cell proliferation and survival. Am J Pathol 2004;164:501-510.
48. Fields AC, Cotsonis G, Sexton D, et al. Survivin expression in hepatocellular carcinoma: correlation with proliferation, prognostic parameters, and outcome. Mod Pathol 2004;17:1378-1385.
49. Okada E, Murai Y, Matsui K, et al. Survivin expression in tumor cell nuclei is predictive of a favorable prognosis in gastric cancer patients. Cancer Lett 2001;163:109-116.
50. Kennedy SM, O'Driscoll L, Purcell R, et al. Prognostic importance of survivin in breast cancer. Br J Cancer 2003;88:1077-1183.
51. Li F, Yang J, Ramnath N, et al. Nuclear or cytoplasmic expression of survivin: what is the significance? Int J Cancer 2005;114:509-512.